达依泊汀联合缓慢释放静脉铁以减少早产儿输血并改善铁状态与神经发育(DIVI):一项随机盲法II期试验的研究方案
本研究为单中心、平行设计、前瞻性、随机对照II期试验,拟纳入120名胎龄24-0/7至31-6/7周早产儿,随机分入口服铁标准治疗组或达依泊汀联合不同剂量缓慢释放静脉铁(ferumoxytol或低分子量右旋糖酐铁)组,主要结局为矫正胎龄34-36周时铁蛋白水平,随访至矫正年龄2岁评估神经发育。
要点
- 试验纳入胎龄24-0/7至31-6/7周早产儿,随机分五组比较口服铁与达依泊汀联合静脉铁方案。
- 主要结局为矫正胎龄34-36周时铁蛋白水平,次要结局包括血液学指标、药物安全性、肠道微生物组及2岁神经发育。
- 该试验旨在确定达依泊汀联合缓慢释放静脉铁是否安全,以及哪种铁剂和剂量最能维持铁充足并减少或消除输血。
核心结论
- 该试验将确定达依泊汀联合缓慢释放静脉铁制剂是否安全,哪种铁制剂和剂量最能维持铁充足并减少或消除输血,与口服铁补充相比静脉铁是否会导致更多样、致病性更低的微生物组,以及这些治疗是否影响至矫正年龄2岁的神经发育。
研究设计与样本
- 单中心、平行设计、前瞻性、随机对照II期试验,纳入120名胎龄24-0/7至31-6/7周、在华盛顿大学新生儿重症监护室接受照护的早产儿。
- 知情同意后,72小时龄内婴儿随机分入五组:口服铁(标准照护)n=40,或每周达依泊汀10 µg/kg/剂静脉或皮下注射联合ferumoxytol 10 mg/kg/剂静脉n=20、ferumoxytol 20 mg/kg/剂静脉n=20、低分子量右旋糖酐铁10 mg/kg/剂静脉n=20、低分子量右旋糖酐铁20 mg/kg/剂静脉n=20。
- 随访至矫正年龄2岁,进行序列发育测试。
主要发现
- 主要结局为矫正胎龄34-36周时铁蛋白水平。
- 次要结局包括其他血液学评估、药物安全性、肠道微生物组评估及至矫正年龄2岁的神经发育。
关键数值与推荐
- 主要结局:矫正胎龄34-36周时铁蛋白水平。
- 次要结局:其他血液学评估、药物安全性、肠道微生物组评估、至矫正年龄2岁的神经发育。
- 试验注册:National Clinical Trial (NCT) NCT05340465,注册于2022年3月1日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infants born preterm are at high risk of anemia, red blood cell transfusions, and iron deficiency, all of which may negatively influence long-term neurodevelopment. To ameliorate these complications of prematurity, we developed a Phase II trial to determine whether treatment with an erythropoietic-stimulating agent, darbepoetin (Darbe), plus a slow-release intravenous (IV) iron preparation (ferumoxytol (FMX) or low-molecular-weight iron dextran (LMW-ID)) might decrease transfusions while maintaining iron sufficiency. METHODS: This single-center study is a parallel design, prospective, randomized controlled Phase II trial of 120 infants born 24-0/7 to 31-6/7 weeks of gestation cared for in the University of Washington Neonatal Intensive Care Unit. After informed consent, infants less than 72 h of age are randomized to one of five treatment groups: (1) Oral iron (standard care), n = 40, or weekly Darbe 10 µg/kg/dose IV or SQ plus; (2) FMX - 10 mg/kg/dose IV, n = 20; (3) FMX - 20 mg/kg/dose IV, n = 20; (4) LMW-ID - 10 mg/kg/dose IV, n = 20; or (5) LMW-ID - 20 mg/kg/dose IV, n = 20. Infants will be followed to 2-year corrected age with sequential developmental testing. Our primary outcome is ferritin level at 34-36 weeks postmenstrual age. Secondary outcomes include other hematologic assessments, drug safety, evaluation of the gut microbiome, and neurodevelopment to 2 years corrected age. DISCUSSION: This trial will determine whether darbepoetin plus a slow-release IV iron preparation is safe, which iron preparation and dose best maintain iron sufficiency and decrease or eliminate transfusions, whether IV iron will result in a more diverse, less pathogenic microbiome when compared to oral iron supplementation, and, finally, whether these treatments affect neurodevelopment to 2 years corrected age. TRIAL REGISTRATION: National Clinical Trial (NCT) NCT05340465. Registered on March 1, 2022.
引用
- Juul SE, Comstock BA, Mayock DE, et al. Darbepoetin plus slow-release IntraVenous Iron to decrease transfusions and improve iron status and neurodevelopment in preterm infants (DIVI): study protocol for a randomized, blinded phase II trial. Trials. 2025. PMID: 41430711. doi:10.1186/s13063-025-09374-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。